David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

Jennifer Silva discusses the importance of discussing black box warnings when utilizing JAK inhibitors in patients with vitiligo.

Dr. Seneschal discusses currently available topical JAKs for vitiligo, systemic JAKs being trialed to treat the condition in the future, and how JAKs can be...

Jennifer Silva discusses a few treatment strategies to utilize in patients who continue to struggle to find effective treatment for their vitiligo.

Iltefat Hamzavi, MD, and JCAD’s Editor-in-Chief, James Del Rosso, DO, discuss topical treatment considerations for patients with vitiligo when using topical ruxolitinib cream, including topical...

Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment...

Gina Mangin discusses effective treatment practice for patients with vitiligo centered around providing encouragement and motivation throughout the process.

Gina Mangin discusses the importance of educating patients on the expected timeline for repigmentation when utilizing light box therapy.

Dr. Elbuluk discusses the importance of assessing the psychological state of patients by gathering social information such as daily activities, living situation, and work status.1...

Shanna Miranti speaks to the importance of trying and failing with topical corticosteroids and topical calcineurin inhibitors prior to prescribing patients with topical ruxolitinib.